person · Reporting owner
Polymeropoulos Mihael Hristos
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director · President and CEO · Chairman of the Board | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,704,496 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 156,235 · Balance 2,704,496 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · derivative · entry 8 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs shall vest in four (4) equal annual installments beginning January 1, 2016, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · derivative · entry 7 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs shall vest in four (4) equal annual installments beginning January 1, 2015, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionRestricted Stock Unit · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · derivative · entry 6 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. F4 · derivative.exercise_date: 50% of the original RSU award vested on July 29, 2013 due to milestone achievement, the remaining RSUs vest in four (4) equal annual installments beginning January 1, 2014, provided Reporting Person has remained in continuous service with the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. F5 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 23,330 | $15.48 | $361,241.72 |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · nonDerivative · entry 5 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,848 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.275 to $15.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · nonDerivative · entry 4 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · nonDerivative · entry 3 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · nonDerivative · entry 2 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-002190 · doc4.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock. Read SEC document |
| December 23, 2016 Filed Feb 6, 2017 22:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008087 · doc5.xml · nonDerivative · entry 1 Polymeropoulos Mihael Hristos · CIK 0001355537 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,178 F1 · kind: Represents a gift to a charitable organization. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.